New study finds lower occurrence of heart failure in older people with type 2.
Read More »Production Assistant, Diabetes In Control
Benefits of CGM’s for Type 1 Patients
Real-time monitoring produces significant long-term improvement in HbA1c.
Read More »CGM Use For Type 1 Pregnant Women Randomized Trial- CONCEPTT Study
Study examined effectiveness of CGM on maternal glucose control and obstetric and neonatal health outcomes.
Read More »Fat and Carbohydrate Intake Affects CVD and Mortality
The pendulum has swung from too much fat to too many carbs.
Read More »Can Screening for Diabetes Reduce CVD and Mortality in General Population?
Even though screening the general population does not impact mortality or CVD incidence, it did have benefits for those diagnosed with diabetes.
Read More »Antihyperglycemic Medications for Patients with Type 2 Diabetes
The American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) list a hierarchy of usage for antihyperglycemic medications after metformin. Which one of the following lists shows the correct hierarchy, beginning with the most preferred? A. A Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sodium-glucose cotransporter 2 (SGLT-2) inhibitors, dipeptidyl peptidase 4 (DPP-4) inhibitors, thiazolidinediones (TZDs), basal insulins B. SGLT-2 inhibitors, DPP-4 inhibitors, GLP-1 RAs, TZDs, basal insulins C. TZDs, GLP-1 RAs, SGLT-2 inhibitors, DPP-4 inhibitors, basal insulins D. GLP-1 RAs, SGLT-2 inhibitors, basal insulins, DPP-4 inhibitors, TZDs Follow the link to see the right answer.
Read More »Will CGMs Replace BG Monitors?
Do you feel that continuous blood glucose monitoring (CGM) will eventually replace blood glucose monitors? Follow the link to share your response.
Read More »Albuminuria: A Lot More Than Just a Little Protein in the Urine Part 5
In this week's Homerun Slides, health conditions potentially indicated by albuminuria levels.
Read More »International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #91: Lipid and Lipoprotein Metabolism, Hypolipidemic Agents, and Therapeutic Goals Part 3
In the fasting state, hepatic VLDL assembly and secretion predominate. Utilization of nascent apo B100 for the assembly and secretion of VLDL is, to a large extent, limited by substrate availability, namely TG, as apo B100 is constitutively synthesized. In the presence of adequate TG, apo B100 is progressively lipidated through the actions of hepatic MTP, and the newly assembled VLDL particle is transported to the Golgi apparatus, where it may undergo further lipidation before secretion into plasma.
Read More »EASD: SGLT-2/GLP-1 Combo Better Than Monotherapy
Trial finds improvement in control and weight loss.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.